Trial Profile
Expansion Cohort Study of Disulfiram and Chemotherapy in Pancreas Cancer Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 14 Feb 2024
Price :
$35
*
At a glance
- Drugs Disulfiram (Primary) ; Gemcitabine (Primary)
- Indications Adenocarcinoma; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- 08 Feb 2024 Planned End Date changed from 5 May 2024 to 5 May 2025.
- 08 Feb 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 13 Jun 2023 Planned End Date changed from 5 May 2023 to 5 May 2024.